Non-coding RNA in the Diagnosis and Prognosis of Myocardial Infarction

Fengming Lai; Dewen Liu; Chen Nong; Wenyu Xie; Yulian Tang; Na Guo; Taizhong Wang

doi:10.54097/2mnxgd43

Authors

Fengming Lai
Dewen Liu
Chen Nong
Wenyu Xie
Yulian Tang
Na Guo
Taizhong Wang

DOI:

https://doi.org/10.54097/2mnxgd43

Keywords:

Myocardial Infarction (MI), Non-coding RNA (ncRNA), Diagnosis, Prognosis

Abstract

This review primarily investigates the role of non-coding RNAs (ncRNAs) in the diagnosis and prognosis of myocardial infarction (MI). MI is a severe cardiovascular disease, largely dependent on traditional biomarkers and electrocardiograms. However, traditional biomarkers such as cardiac troponin (cTn) have limitations, including high false-positive rates, diagnostic complexity, and abnormal expression in multiple diseases. Thus, there is an urgent need for more sensitive and specific novel biomarkers. ncRNAs have been proven to play a crucial role in the pathogenesis of MI affecting the survival, apoptosis, proliferation, and fibrosis of cardiomyocytes. Compared to traditional MI biomarkers, ncRNAs exhibit better sensitivity and specificity, aiding in the rapid, accurate diagnosis and early treatment, thereby providing a better prognosis for patients. This review aims to summarize current research reports on ncRNAs in the diagnosis and prognosis of MI and discuss their limitations, with the hope of deepening the understanding of non-coding genes in MI.

Downloads

Download data is not yet available.

References

[1] LIU Y, DING W, WANG J, et al. Non-coding RNA-mediated modulation of ferroptosis in cardiovascular diseases [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, 164: 114993.

[2] AO X, DING W, LI X, et al. Non-coding RNAs regulating mitochondrial function in cardiovascular diseases [J]. Journal of molecular medicine (Berlin, Germany), 2023, 101(5): 501-26.

[3] HARTIKAINEN T, WESTERMANN D. Advances in rapid diagnostic tests for myocardial infarction patients [J]. Expert Rev Mol Diagn, 2023, 23(5): 391-403.

[4] MORROW D A, CANNON C P, JESSE R L, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes [J]. Circulation, 2007, 115(13): e356-75.

[5] WANG X M, LI X M, SONG N, et al. Corrigendum to "Long non-coding RNAs H19, MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction" [Biomed. Pharmacother. 118(2019)109208] [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, 151: 113206.

[6] MORROW D A, CANNON C P, JESSE R L, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes [J]. Clinical chemistry, 2007, 53(4): 552-74.

[7] ELLIS B W, RONAN G, REN X, et al. Human Heart Anoxia and Reperfusion Tissue (HEART) Model for the Rapid Study of Exosome Bound miRNA Expression As Biomarkers for Myocardial Infarction [J]. Small (Weinheim an der Bergstrasse, Germany), 2022, 18(28): e2201330.

[8] HAAF P, DREXLER B, REICHLIN T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease [J]. Circulation, 2012, 126(1): 31-40.

[9] ABBAS N A, JOHN R I, WEBB M C, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease [J]. Clinical chemistry, 2005, 51(11): 2059-66.

[10] FINSTERER J, STöLLBERGER C, KRUGLUGER W. Cardiac and noncardiac, particularly neuromuscular, disease with troponin-T positivity [J]. Neth J Med, 2007, 65(8): 289-95.

[11] DEVAUX Y, VAUSORT M, GORETTI E, et al. Use of circulating microRNAs to diagnose acute myocardial infarction [J]. Clinical chemistry, 2012, 58(3): 559-67.

[12] FADAEI S, ZAREPOUR F, PARVARESH M, et al. Epigenetic regulation in myocardial infarction: Non-coding RNAs and exosomal non-coding RNAs [J]. Frontiers in cardiovascular medicine, 2022, 9: 1014961.

[13] ZHANG Y, JIA D D, ZHANG Y F, et al. The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases [J]. Int J Biol Sci, 2021, 17(7): 1731-41.

[14] ZHANG L, ZHANG Y, YU F, et al. The circRNA-miRNA/RBP regulatory network in myocardial infarction [J]. Frontiers in pharmacology, 2022, 13: 941123.

[15] ZHU L, LI N, SUN L, et al. Non-coding RNAs: The key detectors and regulators in cardiovascular disease [J]. Genomics, 2021, 113(1 Pt 2): 1233-46.

[16] AI J, ZHANG R, LI Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction [J]. Biochem Biophys Res Commun, 2010, 391(1): 73-7.

[17] LI J, MA H, WU X, et al. Promising roles of non-exosomal and exosomal non-coding RNAs in the regulatory mechanism and as diagnostic biomarkers in myocardial infarction [J]. Journal of Zhejiang University Science B, 2023, 24(4): 281-300.

[18] ALMAGHRBI H, GIORDO R, PINTUS G, et al. Non-coding RNAs as biomarkers of myocardial infarction [J]. Clin Chim Acta, 2023, 540: 117222.

[19] HA T Y. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease [J]. Immune network, 2011, 11(3): 135-54.

[20] WU A H, FENG Y J. Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes [J]. European heart journal, 1998, 19 Suppl N: N25-9.

[21] WANG G K, ZHU J Q, ZHANG J T, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans [J]. European heart journal, 2010, 31(6): 659-66.

[22] KUWABARA Y, ONO K, HORIE T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage [J]. Circulation Cardiovascular genetics, 2011, 4(4): 446-54.

[23] LIU C, ZHENG H, XIE L, et al. Decreased miR-208 induced ischemia myocardial and reperfusion injury by targeting p21 [J]. Pharmazie, 2016, 71(12): 719-23.

[24] ZHAI C, LI R, HOU K, et al. Value of Blood-Based microRNAs in the Diagnosis of Acute Myocardial Infarction: A Systematic Review and Meta-Analysis [J]. Frontiers in physiology, 2020, 11: 691.

[25] LV P, ZHOU M, HE J, et al. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction [J]. Int J Mol Sci, 2014, 15(4): 5774-88.

[26] XUE S, LIU D, ZHU W, et al. Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p Are Novel Biomarkers for Diagnosis of Acute Myocardial Infarction [J]. Frontiers in physiology, 2019, 10: 123.

[27] ZHAO J, YU H, YAN P, et al. Circulating MicroRNA-499 as a Diagnostic Biomarker for Acute Myocardial Infarction: A Meta-analysis [J]. Disease markers, 2019, 2019: 6121696.

[28] RAO P K, TOYAMA Y, CHIANG H R, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure [J]. Circ Res, 2009, 105(6): 585-94.

[29] PAN Z, SUN X, REN J, et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models [J]. PLoS One, 2012, 7(11): e50515.

[30] PENG L, CHUN-GUANG Q, BEI-FANG L, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction [J]. Diagnostic pathology, 2014, 9: 89.

[31] SOTHIVELR V, HASAN M Y, MOHD SAFFIAN S, et al. Revisiting miRNA-21 as a Therapeutic Strategy for Myocardial Infarction: A Systematic Review [J]. J Cardiovasc Pharmacol, 2022, 80(3): 393-406.

[32] JAYAWARDENA E, MEDZIKOVIC L, RUFFENACH G, et al. Role of miRNA-1 and miRNA-21 in Acute Myocardial Ischemia-Reperfusion Injury and Their Potential as Therapeutic Strategy [J]. Int J Mol Sci, 2022, 23(3).

[33] WANG X M, LI X M, SONG N, et al. Long non-coding RNAs H19, MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, 118: 109208.

[34] JI P, DIEDERICHS S, WANG W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer [J]. Oncogene, 2003, 22(39): 8031-41.

[35] VAUSORT M, WAGNER D R, DEVAUX Y. Long noncoding RNAs in patients with acute myocardial infarction [J]. Circ Res, 2014, 115(7): 668-77.

[36] LI R, JIN J, LIU E, et al. A novel circulating biomarker lnc-MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events [J]. Journal of clinical laboratory analysis, 2022, 36(12): e24771.

[37] YANG X, DAI R, QIN Z, et al. LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention [J]. Scientific reports, 2022, 12(1): 3294.

[38] HAN Y, DONG B, CHEN M, et al. LncRNA H19 suppresses pyroptosis of cardiomyocytes to attenuate myocardial infarction in a PBX3/CYP1B1-dependent manner [J]. Molecular and cellular biochemistry, 2021, 476(3): 1387-400.

[39] LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A [J]. Journal of cellular and molecular medicine, 2023, 27(12): 1757-60.

[40] ISHII N, OZAKI K, SATO H, et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction [J]. J Hum Genet, 2006, 51(12): 1087-99.

[41] QU X, DU Y, SHU Y, et al. MIAT Is a Pro-fibrotic Long Non-coding RNA Governing Cardiac Fibrosis in Post-infarct Myocardium [J]. Scientific reports, 2017, 7: 42657.

[42] CAO X, MA Q, WANG B, et al. Silencing long non-coding RNA MIAT ameliorates myocardial dysfunction induced by myocardial infarction via MIAT/miR-10a-5p/EGR2 axis [J]. Aging, 2021, 13(8): 11188-206.

[43] WU Z, ZHAO S, LI C, et al. LncRNA TUG1 serves an important role in hypoxia-induced myocardial cell injury by regulating the miR‑145‑5p‑Binp3 axis [J]. Molecular medicine reports, 2018, 17(2): 2422-30.

[44] ZHANG S, WANG N, MA Q, et al. LncRNA TUG1 acts as a competing endogenous RNA to mediate CTGF expression by sponging miR-133b in myocardial fibrosis after myocardial infarction [J]. Cell Biol Int, 2021, 45(12): 2534-43.

[45] LI B, WU Y. LncRNA TUG1 overexpression promotes apoptosis of cardiomyocytes and predicts poor prognosis of myocardial infarction [J]. Journal of clinical pharmacy and therapeutics, 2020, 45(6): 1452-6.

[46] VAUSORT M, SALGADO-SOMOZA A, ZHANG L, et al. Myocardial Infarction-Associated Circular RNA Predicting Left Ventricular Dysfunction [J]. J Am Coll Cardiol, 2016, 68(11): 1247-8.

[47] HUANG S, LI X, ZHENG H, et al. Loss of Super-Enhancer-Regulated circRNA Nfix Induces Cardiac Regeneration After Myocardial Infarction in Adult Mice [J]. Circulation, 2019, 139(25): 2857-76.

[48] YANG W, SUN L, CAO X, et al. Detection of circRNA Biomarker for Acute Myocardial Infarction Based on System Biological Analysis of RNA Expression [J]. Front Genet, 2021, 12: 686116.

[49] SALGADO-SOMOZA A, ZHANG L, VAUSORT M, et al. The circular RNA MICRA for risk stratification after myocardial infarction [J]. Int J Cardiol Heart Vasc, 2017, 17: 33-6.

[50] ZHANG M, WANG Z, CHENG Q, et al. Circular RNA (circRNA) CDYL Induces Myocardial Regeneration by ceRNA After Myocardial Infarction [J]. Medical science monitor: international medical journal of experimental and clinical research, 2020, 26: e923188.

[51] RAJAN K S, VELMURUGAN G, GOPAL P, et al. Abundant and Altered Expression of PIWI-Interacting RNAs during Cardiac Hypertrophy [J]. Heart, lung & circulation, 2016, 25(10): 1013-20.